Low-Dose Rituximab Effective Against MuSK-Positive MG in New Analysis

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Related Keywords

Neurosci Lett ,Michael Benatar ,Shanxi Medical University ,Myasthenia Gravis Foundation Of America ,Neurology Department Of First Hospital ,Image Credit ,Neuroscience Letters ,Neurology Department ,First Hospital ,Myasthenia Gravis Foundation ,America Post Intervention Status ,Quantitative Myasthenia Gravis ,Myasthenia Gravis Quality ,Low Dose Rituximab ,Rituximab ,Mg Adl ,Musk Mg ,